��������

Dr. Fraenkel serves as a Scientific Advisor to PrognomiQ. He is Professor of Biological Engineering at MIT and an Associate Member of the Broad Institute. He is recognized as a leader in the development of novel computational and experimental methods to uncover new therapeutic approaches to disease. His research utilizes multiple experimental methods to measure cellular changes across the genome and proteome, and then computationally integrates these diverse sets of data to reveal novel signaling pathways and regulatory mechanisms that may lead to new therapies for disease. His current projects focus on the study of cancer and neurodegenerative diseases. Dr. Fraenkel received his A.B. from Harvard College and Ph.D. from MIT.